Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases
about
A practical guide about biosimilar data for health care providers treating inflammatory diseasesSystematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases.Comparative effectiveness of the biosimilar CT-P13.Path of Interchangeability of Biosimilars in Pediatric Inflammatory Bowel Disease: Quality Before Cost Savings.Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
P2860
Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases
description
2016 nî lūn-bûn
@nan
2016 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Experience with biosimilar inf ...... th inflammatory bowel diseases
@ast
Experience with biosimilar inf ...... th inflammatory bowel diseases
@en
Experience with biosimilar inf ...... th inflammatory bowel diseases
@nl
type
label
Experience with biosimilar inf ...... th inflammatory bowel diseases
@ast
Experience with biosimilar inf ...... th inflammatory bowel diseases
@en
Experience with biosimilar inf ...... th inflammatory bowel diseases
@nl
prefLabel
Experience with biosimilar inf ...... th inflammatory bowel diseases
@ast
Experience with biosimilar inf ...... th inflammatory bowel diseases
@en
Experience with biosimilar inf ...... th inflammatory bowel diseases
@nl
P2860
P50
P356
P1476
Experience with biosimilar inf ...... th inflammatory bowel diseases
@en
P2093
J. Sieczkowska
P2860
P304
P356
10.1177/1756283X16650155
P407
P577
2016-09-01T00:00:00Z